Neumora Therapeutics Reports Disappointing Phase 3 Results for Navacaprant, Announces Pipeline Prioritization and Major Restructuring
Watertown, Mass., June 15, 2026 – Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has released critical updates following the results of its Phase 3 KOASTAL-2 and KOASTAL-3 trials for navacaprant in major depressive disorder (MDD). The company also provided an update on its pipeline and announced significant organizational changes.
Key Highlights for Investors
- Navacaprant Fails to Meet Endpoints in Phase 3 Trials: The KOASTAL-2 and KOASTAL-3 studies evaluating navacaprant for MDD did not achieve statistical significance on either the primary or key secondary endpoints. As a result, Neumora will discontinue all development of navacaprant.
- Significant Restructuring Announced: In response to the failed studies, Neumora will reduce its workforce by approximately 35%, expecting annualized cost savings of approximately \$10 million, partially offset by one-time restructuring costs of around \$2 million.
- Cash Runway Extended: The company projects its current cash and cash equivalents will support operations into the third quarter of 2027, including reaching multiple significant clinical milestones.
-
Pipeline Refocus on ‘Best-in-Class’ Assets: Neumora will now prioritize and advance its other clinical programs, including:
- NMRA-511 (V1a receptor antagonist for Alzheimer’s disease agitation): Multiple ascending dose cohorts in healthy elderly volunteers are expected to be completed in Q4 2026. Data from this study will inform the design and dose selection for a planned Phase 2b trial by the end of 2026.
- NMRA-898 (M4 positive allosteric modulator for schizophrenia): Data readout from the ongoing Phase 1 study is expected in the second half of 2026.
- NMRA-215 (NLRP3 inhibitor for obesity/cardiometabolic disease): Completion of a repeat 13-week rat toxicology study is anticipated by mid-2026, with a program update planned alongside Q2 financial results in August 2026. Initial clinical studies are targeted for launch by year-end 2026.
-
KOASTAL Study Details: The KOASTAL-2 and KOASTAL-3 trials enrolled 430 and 422 adult MDD patients, respectively. Efficacy results showed no advantage for navacaprant over placebo:
- KOASTAL-2: Navacaprant 80mg (n=217) vs. placebo (n=213): Mean change from baseline (CFB) in MADRS at week 6 was -12.2 vs. -12.0 (LSMD = -0.3; p = 0.813).
- KOASTAL-3: Navacaprant 80mg (n=212) vs. placebo (n=210): CFB -10.1 vs. -10.8 (LSMD = 0.7; p = 0.480).
- Post-optimization pooled analysis: Navacaprant (n=216) vs. placebo (n=210): CFB -12.1 vs. -12.1 (LSMD = 0.0; p = 0.976).
- Safety Profile: Navacaprant was found to be safe and generally well tolerated, with a safety profile consistent with prior studies.
Potential Impact on Shareholders
- Discontinuation of Navacaprant: The failure of navacaprant, previously a lead asset, is a significant setback. Discontinuation of this program could have an immediate negative impact on investor sentiment and share price, especially for shareholders who valued the asset’s potential in MDD.
- Major Cost-Cutting and Restructuring: While the 35% workforce reduction and associated cost savings may stabilize the company’s financial position, it also highlights the scale of the clinical setback and could raise concerns about the company’s long-term growth prospects.
- Focus on Pipeline Opportunities: The company’s pivot to NMRA-511, NMRA-898, and NMRA-215 represents a strategic refocus. Upcoming catalysts, such as clinical readouts and study initiations throughout 2026 and into 2027, are now the main potential share price drivers.
- Financial Stability: The projected cash runway into Q3 2027 provides operational stability, allowing Neumora to pursue its pipeline without immediate financing concerns.
Management Commentary
“While we are disappointed with the results of the KOASTAL-2 and -3 studies, we want to extend our gratitude to the patients, families, dedicated investigators, Neumora team and others who contributed meaningfully to the KOASTAL program,” said Bill Aurora, Pharm.D., Chief Operating and Development Officer.
CEO Paul L. Berns added, “We remain excited about the best-in-class potential of our pipeline… We look forward to the key catalysts we expect for NMRA-511 in Alzheimer’s disease agitation, NMRA-898 in schizophrenia, and NMRA-215 in cardiometabolic disease over the next 12 months.”
Summary
Neumora’s latest report delivers a mix of negative and forward-looking news. The failure of navacaprant in late-stage MDD trials and associated discontinuation is a major negative catalyst, offset to some extent by a clear focus on potentially high-value pipeline assets and a strengthened financial position. Investors should monitor upcoming milestones for the NMRA-511, NMRA-898, and NMRA-215 programs as these will be critical for restoring value and market confidence. The significant restructuring and cost-saving measures may provide stability but also underscore the impact of the pipeline setback.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that may materially affect actual results. Investors should review all official filings and consult their own advisors before making investment decisions.
